EICHOR
● Completed
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Topical ESR-114 in Subjects With Plaque Psoriasis
Condition: Psoriatic Plaque · Sponsor: Escalier Biosciences B.V.
About this study
This is a multicenter, double-blind, randomized, vehicle-controlled, parallel-group proof-of-concept study designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of topically applied ESR-114 following twice daily (BID) application for 42 days (6 weeks).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (10)
| Study Site 19 | Santa Monica, California, United States | — |
| Study Site 16 | Tampa, Florida, United States | — |
| Study Site 17 | Fridley, Minnesota, United States | — |
| Study Site 14 | Raleigh, North Carolina, United States | — |
| Study Site 12 | Austin, Texas, United States | — |
| Study Site 11 | College Station, Texas, United States | — |
| Study Site 15 | Houston, Texas, United States | — |
| Study Site 18 | San Antonio, Texas, United States | — |
| Study Site 13 | Peterborough, Ontario, Canada | — |
| Study Site 10 | Montreal, Quebec, Canada | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03630939